TXMD - TherapeuticsMD rallies; to meet Q3 revenue consensus
TherapeuticsMD (TXMD) +6.1% PM, believes that the company is on track to meet or exceed Q3 total net revenue consensus of $15.1M.For the ANNOVERA product, orders to wholesalers, retail pharmacies and online distributors across Q3 have increased that are greater than the patient demand numbers being reported by industry prescription tracking databases.Weekly inventory on hand reported by wholesalers remains consistent over the quarter.It is well positioned to meet or exceed Q3 total net revenue consensus thereby on a strong trajectory for Q4.
For further details see:
TherapeuticsMD rallies; to meet Q3 revenue consensus